共 61 条
[1]
Mariotto AB(2017)Estimation of the number of women living with metastatic breast cancer in the united states Cancer Epidemiol Biomarkers Prev 26 809-815
[2]
Etzioni R(2017)Impact of molecular subtypes on metastatic breast cancer patients: a seer population-based study Sci Rep 7 45411-590
[3]
Hurlbert M(2018)Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010 Breast Cancer Res Treat 167 579-2910
[4]
Penberthy L(2021)Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update J Clin Oncol 21 2905-1936
[5]
Mayer M(2015)Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment Clin Cancer Res 375 1925-1748
[6]
Gong Y(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1738-915
[7]
Liu YR(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 19 904-3646
[8]
Ji P(2018)Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Lancet Oncol 35 3638-1936
[9]
Hu X(2017)MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 379 1926-524
[10]
Shao ZM(2018)Overall survival with palbociclib and fulvestrant in advanced breast cancer N Engl J Med 382 514-124